Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin

JT Babcock, LA Quilliam - Current drug targets, 2011 - ingentaconnect.com
mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by
the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this drug …
被引用次数：27 相关文章

Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin

JT Babcock, LA Quilliam - Current drug targets, 2011 - pubmed.ncbi.nlm.nih.gov
mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by
the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this durg …

Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin.

JT Babcock, LA Quilliam - Current Drug Targets, 2011 - europepmc.org
mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by
the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this durg …

[引用][C] Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin

JT Babcock, LA Quilliam - Current Drug Targets, 2011 - cir.nii.ac.jp
Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond
Rapamycin | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …